Since BioEurope is one of the main events for partnering and drug development collaborations, Redoxis is during 4-6 April in Stockholm attending the BioEurope event where we are meeting new partners, Sponsors for Redoxis preclinical capacities for autoimmune conditions.

We are also initiating work in the subsidiary company ProNoxis to meet partners for co-development of anti-inflammatory NOX2 agonist lead compounds.